Chimeric antigen receptor engineering: A right step in the evolution of adoptive cellular immunotherapy

Jose A. Figueroa, Adair Reidy, Leonardo Mirandola, Kayley Trotter, Natallia Suvorava, Alejandro Figueroa, Venu Konala, Amardeep Aulakh, Lauren Littlefield, Fabio Grizzi, Rakhshanda Layeequr Rahman, Marjorie R. Jenkins, Breeanna Musgrove, Saba Radhi, Nicholas D'Cunha, Luke N. D'Cunha, Paul L. Hermonat, Everardo Cobos, Maurizio Chiriva-Internati

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Cancer immunotherapy comprises different therapeutic strategies that exploit the use of distinct components of the immune system, with the common goal of specifically targeting and eradicating neoplastic cells. These varied approaches include the use of specific monoclonal antibodies, checkpoint inhibitors, cytokines, therapeutic cancer vaccines and cellular anticancer strategies such as activated dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs) and, more recently, genetically engineered T cells. Each one of these approaches has demonstrated promise, but their generalized success has been hindered by the paucity of specific tumor targets resulting in suboptimal tumor responses and unpredictable toxicities. This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer.

Original languageEnglish
Pages (from-to)154-187
Number of pages34
JournalInternational Reviews of Immunology
Volume34
Issue number2
DOIs
Publication statusPublished - Mar 4 2015

Fingerprint

Adoptive Immunotherapy
Antigen Receptors
Neoplasms
T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Cancer Vaccines
Immunotherapy
Dendritic Cells
Immune System
Vaccines
Monoclonal Antibodies
Cytokines
Therapeutics

Keywords

  • AAV: adeno-associated virus
  • ACI: adoptive cellular immunotherapy
  • Ad: adenovirus
  • AKAP4: A-kinase anchoring protein 4
  • ALL: acute lymphoblastic leukemia
  • AlloSCT: allogeneic stem cell transplant
  • AML: acute myeloid leukemia
  • ASP: AKAP-associated sperm protein
  • CAIX: carbonic anhydrase-IX
  • CAR: chimeric antigen receptor
  • CAReTC: chimeric antigen receptor-engineered T cell
  • CEA: carcinoembryonic antigen
  • CLL: chronic lymphocytic leukemia
  • CTA: cancer testis antigen
  • CTL: cytotoxic T lymphocyte
  • DC: dendritic cell
  • EBV: Epstein-Bar virus
  • ERK: extracellular signal-regulated kinase
  • FAP: fibroblast activation protein
  • FITC: fluorescein isothiocyanate
  • GVHD: graft-vs.-host disease
  • HAMA: human anti-mouse antibodies
  • HLA: human leukocyte antigen
  • HSCT: hematopoietic stem cell transplant
  • HSV: herpes simplex virus
  • HvG: host versus graft
  • IL-1, IL-2: interleukin-1, interleukin-2
  • ITR: inverted terminal repeat
  • JNK: c-Jun N-terminal kinase
  • LAK: lymphokine activated killer cell
  • Ly-CM: lymphocyte-conditioned medium
  • MHC: major histocompatibility complex
  • NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells
  • NFAT: nuclear factor of activated T cell
  • NHL: Non-Hodgkin's lymphoma
  • NK: natural killer
  • NKG2D: natural killer receptor G2D
  • PD-1: programmed death-1
  • PKA: protein A-kinase
  • RAAV: recombinant AAV
  • ScFv: single-chain variable fragment
  • SIRS: systemic inflammatory response syndrome
  • SP17: sperm protein 17
  • TAA: tumor-associating antigen
  • TCM: central memory T cell
  • TCR: T-cell receptors
  • TE: effector T cell
  • TEM: effector memory T cell
  • TH: helper T cell
  • TIL: tumor-infiltrating lymphocyte
  • TNF: tumor necrosis factor
  • TRAF: TNF receptor-associated factor
  • Treg: regulatory T cell
  • TRUCK: T cells redirected for universal cytokine killing
  • TSCM: stem cell memory T cell

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Figueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., ... Chiriva-Internati, M. (2015). Chimeric antigen receptor engineering: A right step in the evolution of adoptive cellular immunotherapy. International Reviews of Immunology, 34(2), 154-187. https://doi.org/10.3109/08830185.2015.1018419

Chimeric antigen receptor engineering : A right step in the evolution of adoptive cellular immunotherapy. / Figueroa, Jose A.; Reidy, Adair; Mirandola, Leonardo; Trotter, Kayley; Suvorava, Natallia; Figueroa, Alejandro; Konala, Venu; Aulakh, Amardeep; Littlefield, Lauren; Grizzi, Fabio; Rahman, Rakhshanda Layeequr; R. Jenkins, Marjorie; Musgrove, Breeanna; Radhi, Saba; D'Cunha, Nicholas; D'Cunha, Luke N.; Hermonat, Paul L.; Cobos, Everardo; Chiriva-Internati, Maurizio.

In: International Reviews of Immunology, Vol. 34, No. 2, 04.03.2015, p. 154-187.

Research output: Contribution to journalArticle

Figueroa, JA, Reidy, A, Mirandola, L, Trotter, K, Suvorava, N, Figueroa, A, Konala, V, Aulakh, A, Littlefield, L, Grizzi, F, Rahman, RL, R. Jenkins, M, Musgrove, B, Radhi, S, D'Cunha, N, D'Cunha, LN, Hermonat, PL, Cobos, E & Chiriva-Internati, M 2015, 'Chimeric antigen receptor engineering: A right step in the evolution of adoptive cellular immunotherapy', International Reviews of Immunology, vol. 34, no. 2, pp. 154-187. https://doi.org/10.3109/08830185.2015.1018419
Figueroa, Jose A. ; Reidy, Adair ; Mirandola, Leonardo ; Trotter, Kayley ; Suvorava, Natallia ; Figueroa, Alejandro ; Konala, Venu ; Aulakh, Amardeep ; Littlefield, Lauren ; Grizzi, Fabio ; Rahman, Rakhshanda Layeequr ; R. Jenkins, Marjorie ; Musgrove, Breeanna ; Radhi, Saba ; D'Cunha, Nicholas ; D'Cunha, Luke N. ; Hermonat, Paul L. ; Cobos, Everardo ; Chiriva-Internati, Maurizio. / Chimeric antigen receptor engineering : A right step in the evolution of adoptive cellular immunotherapy. In: International Reviews of Immunology. 2015 ; Vol. 34, No. 2. pp. 154-187.
@article{e9438f3703bb47d9ab8b6919033c9af4,
title = "Chimeric antigen receptor engineering: A right step in the evolution of adoptive cellular immunotherapy",
abstract = "Cancer immunotherapy comprises different therapeutic strategies that exploit the use of distinct components of the immune system, with the common goal of specifically targeting and eradicating neoplastic cells. These varied approaches include the use of specific monoclonal antibodies, checkpoint inhibitors, cytokines, therapeutic cancer vaccines and cellular anticancer strategies such as activated dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs) and, more recently, genetically engineered T cells. Each one of these approaches has demonstrated promise, but their generalized success has been hindered by the paucity of specific tumor targets resulting in suboptimal tumor responses and unpredictable toxicities. This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer.",
keywords = "AAV: adeno-associated virus, ACI: adoptive cellular immunotherapy, Ad: adenovirus, AKAP4: A-kinase anchoring protein 4, ALL: acute lymphoblastic leukemia, AlloSCT: allogeneic stem cell transplant, AML: acute myeloid leukemia, ASP: AKAP-associated sperm protein, CAIX: carbonic anhydrase-IX, CAR: chimeric antigen receptor, CAReTC: chimeric antigen receptor-engineered T cell, CEA: carcinoembryonic antigen, CLL: chronic lymphocytic leukemia, CTA: cancer testis antigen, CTL: cytotoxic T lymphocyte, DC: dendritic cell, EBV: Epstein-Bar virus, ERK: extracellular signal-regulated kinase, FAP: fibroblast activation protein, FITC: fluorescein isothiocyanate, GVHD: graft-vs.-host disease, HAMA: human anti-mouse antibodies, HLA: human leukocyte antigen, HSCT: hematopoietic stem cell transplant, HSV: herpes simplex virus, HvG: host versus graft, IL-1, IL-2: interleukin-1, interleukin-2, ITR: inverted terminal repeat, JNK: c-Jun N-terminal kinase, LAK: lymphokine activated killer cell, Ly-CM: lymphocyte-conditioned medium, MHC: major histocompatibility complex, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells, NFAT: nuclear factor of activated T cell, NHL: Non-Hodgkin's lymphoma, NK: natural killer, NKG2D: natural killer receptor G2D, PD-1: programmed death-1, PKA: protein A-kinase, RAAV: recombinant AAV, ScFv: single-chain variable fragment, SIRS: systemic inflammatory response syndrome, SP17: sperm protein 17, TAA: tumor-associating antigen, TCM: central memory T cell, TCR: T-cell receptors, TE: effector T cell, TEM: effector memory T cell, TH: helper T cell, TIL: tumor-infiltrating lymphocyte, TNF: tumor necrosis factor, TRAF: TNF receptor-associated factor, Treg: regulatory T cell, TRUCK: T cells redirected for universal cytokine killing, TSCM: stem cell memory T cell",
author = "Figueroa, {Jose A.} and Adair Reidy and Leonardo Mirandola and Kayley Trotter and Natallia Suvorava and Alejandro Figueroa and Venu Konala and Amardeep Aulakh and Lauren Littlefield and Fabio Grizzi and Rahman, {Rakhshanda Layeequr} and {R. Jenkins}, Marjorie and Breeanna Musgrove and Saba Radhi and Nicholas D'Cunha and D'Cunha, {Luke N.} and Hermonat, {Paul L.} and Everardo Cobos and Maurizio Chiriva-Internati",
year = "2015",
month = "3",
day = "4",
doi = "10.3109/08830185.2015.1018419",
language = "English",
volume = "34",
pages = "154--187",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Chimeric antigen receptor engineering

T2 - A right step in the evolution of adoptive cellular immunotherapy

AU - Figueroa, Jose A.

AU - Reidy, Adair

AU - Mirandola, Leonardo

AU - Trotter, Kayley

AU - Suvorava, Natallia

AU - Figueroa, Alejandro

AU - Konala, Venu

AU - Aulakh, Amardeep

AU - Littlefield, Lauren

AU - Grizzi, Fabio

AU - Rahman, Rakhshanda Layeequr

AU - R. Jenkins, Marjorie

AU - Musgrove, Breeanna

AU - Radhi, Saba

AU - D'Cunha, Nicholas

AU - D'Cunha, Luke N.

AU - Hermonat, Paul L.

AU - Cobos, Everardo

AU - Chiriva-Internati, Maurizio

PY - 2015/3/4

Y1 - 2015/3/4

N2 - Cancer immunotherapy comprises different therapeutic strategies that exploit the use of distinct components of the immune system, with the common goal of specifically targeting and eradicating neoplastic cells. These varied approaches include the use of specific monoclonal antibodies, checkpoint inhibitors, cytokines, therapeutic cancer vaccines and cellular anticancer strategies such as activated dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs) and, more recently, genetically engineered T cells. Each one of these approaches has demonstrated promise, but their generalized success has been hindered by the paucity of specific tumor targets resulting in suboptimal tumor responses and unpredictable toxicities. This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer.

AB - Cancer immunotherapy comprises different therapeutic strategies that exploit the use of distinct components of the immune system, with the common goal of specifically targeting and eradicating neoplastic cells. These varied approaches include the use of specific monoclonal antibodies, checkpoint inhibitors, cytokines, therapeutic cancer vaccines and cellular anticancer strategies such as activated dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs) and, more recently, genetically engineered T cells. Each one of these approaches has demonstrated promise, but their generalized success has been hindered by the paucity of specific tumor targets resulting in suboptimal tumor responses and unpredictable toxicities. This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer.

KW - AAV: adeno-associated virus

KW - ACI: adoptive cellular immunotherapy

KW - Ad: adenovirus

KW - AKAP4: A-kinase anchoring protein 4

KW - ALL: acute lymphoblastic leukemia

KW - AlloSCT: allogeneic stem cell transplant

KW - AML: acute myeloid leukemia

KW - ASP: AKAP-associated sperm protein

KW - CAIX: carbonic anhydrase-IX

KW - CAR: chimeric antigen receptor

KW - CAReTC: chimeric antigen receptor-engineered T cell

KW - CEA: carcinoembryonic antigen

KW - CLL: chronic lymphocytic leukemia

KW - CTA: cancer testis antigen

KW - CTL: cytotoxic T lymphocyte

KW - DC: dendritic cell

KW - EBV: Epstein-Bar virus

KW - ERK: extracellular signal-regulated kinase

KW - FAP: fibroblast activation protein

KW - FITC: fluorescein isothiocyanate

KW - GVHD: graft-vs.-host disease

KW - HAMA: human anti-mouse antibodies

KW - HLA: human leukocyte antigen

KW - HSCT: hematopoietic stem cell transplant

KW - HSV: herpes simplex virus

KW - HvG: host versus graft

KW - IL-1, IL-2: interleukin-1, interleukin-2

KW - ITR: inverted terminal repeat

KW - JNK: c-Jun N-terminal kinase

KW - LAK: lymphokine activated killer cell

KW - Ly-CM: lymphocyte-conditioned medium

KW - MHC: major histocompatibility complex

KW - NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells

KW - NFAT: nuclear factor of activated T cell

KW - NHL: Non-Hodgkin's lymphoma

KW - NK: natural killer

KW - NKG2D: natural killer receptor G2D

KW - PD-1: programmed death-1

KW - PKA: protein A-kinase

KW - RAAV: recombinant AAV

KW - ScFv: single-chain variable fragment

KW - SIRS: systemic inflammatory response syndrome

KW - SP17: sperm protein 17

KW - TAA: tumor-associating antigen

KW - TCM: central memory T cell

KW - TCR: T-cell receptors

KW - TE: effector T cell

KW - TEM: effector memory T cell

KW - TH: helper T cell

KW - TIL: tumor-infiltrating lymphocyte

KW - TNF: tumor necrosis factor

KW - TRAF: TNF receptor-associated factor

KW - Treg: regulatory T cell

KW - TRUCK: T cells redirected for universal cytokine killing

KW - TSCM: stem cell memory T cell

UR - http://www.scopus.com/inward/record.url?scp=84928565398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928565398&partnerID=8YFLogxK

U2 - 10.3109/08830185.2015.1018419

DO - 10.3109/08830185.2015.1018419

M3 - Article

C2 - 25901860

AN - SCOPUS:84928565398

VL - 34

SP - 154

EP - 187

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 2

ER -